Lowering Plasma Cholesterol by Raising LDL Receptors — Revisited
Year: 2012
Type: editorial
Abstract: Thirty-one years ago, Mabuchi and colleagues1 reported in the Journal that a statin called compactin reduced plasma low-density lipoprotein (LDL) cholesterol levels by 29% in patients with heterozygous familial hypercholesterolemia. This drug inhibits an early step in cholesterol synthesis catalyzed by the enzyme 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase. In an accompanying editorial entitled “Lowering Cholesterol by Raising LDL Receptors,” Brown and Goldstein2 noted that heterozygotes for familial hypercholesterolemia have a deficiency of LDL receptors on cells, resulting in reduced cholesterol uptake by cells and high levels of cholesterol in the plasma. They explained that cholesterol levels within cells are tightly controlled, . . .
Source: New England Journal of Medicine
DOI: 10.1056/nejme1202168
Authors: Stephen G. Young, Loren G. Fong
Institution: University of California, Los Angeles
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2003137291
